Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report)'s stock price fell 3.4% during mid-day trading on Tuesday . The stock traded as low as $3.71 and last traded at $3.69. 710 shares were traded during mid-day trading, a decline of 95% from the average session volume of 14,961 shares. The stock had previously closed at $3.82.
Wall Street Analysts Forecast Growth
Separately, Lifesci Capital began coverage on shares of Molecular Partners in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $12.00 target price for the company.
Get Our Latest Research Report on Molecular Partners
Molecular Partners Stock Up 0.3%
The firm's 50-day moving average is $3.85 and its 200-day moving average is $4.39. The company has a market capitalization of $150.21 million, a PE ratio of -1.94 and a beta of 1.10.
Molecular Partners (NASDAQ:MOLN - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.11). As a group, equities research analysts predict that Molecular Partners AG Sponsored ADR will post -1.93 EPS for the current year.
Institutional Trading of Molecular Partners
A hedge fund recently raised its stake in Molecular Partners stock. BVF Inc. IL raised its holdings in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) by 205.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,353,968 shares of the company's stock after buying an additional 910,747 shares during the period. BVF Inc. IL owned about 3.35% of Molecular Partners worth $6,458,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.55% of the company's stock.
About Molecular Partners
(
Get Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Recommended Stories
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
